Teva Pharmaceutical (TEVA) and Sanofi (SNY) on Tuesday reported that their investigational TL1A antibody duvakitug showed sustained clinical and endoscopic benefits through 44 weeks in ulcerative colitis (UC) and Crohn’s patients who responded in the initial phase of the RELIEVE UCCD extension study.
RELIEVE UCCD LTE is a double-blind randomized study evaluating the long-term efficacy, safety, and tolerability of duvakitug in UC and CD, the two most common forms of inflammatory bowel disease.
These longer duration data reinforce the efficacy from the RELIEVE UCCD phase 2b induction study, which demonstrated that patients achieved clinically meaningful responses with duvakitug compared to placebo at week 14, the companies said in a statement.
Teva Pharmaceutical Industries (TEVA) shares rose 2.7% in premarket trading, while Sanofi gained 0.46%.
